- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07796503
TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass (TSBL-OAGB)
TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass: Interim Results of a Randomized Trial
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This is a single-center, prospective, randomized controlled trial comparing two methods for determining biliopancreatic limb length (BPLL) during laparoscopic one-anastomosis gastric bypass (OAGB) in patients with morbid obesity. Eligible patients aged 18-65 years with BMI ≥35 kg/m² (non-Asian) or ≥32.5 kg/m² (Asian populations) who were candidates for primary OAGB were randomized 1:1 using a computer-generated randomization sequence with sequentially numbered, opaque sealed envelopes.
In the intervention (TSBL-based) group, total small bowel length (TSBL) was measured intraoperatively from the ligament of Treitz to the ileocecal valve, and BPLL was calculated as 0.35 × TSBL. In the control (BMI-based) group, BPLL was determined using standard fixed lengths based on BMI category (150 cm, 180 cm, or 200 cm). All other surgical steps were identical between groups.
The primary outcome is percentage excess weight loss (%EWL) assessed longitudinally at baseline, 3, 6, and 12 months. Secondary outcomes include percentage total weight loss (%TWL), BMI, BMI loss, improvement of obesity-related comorbidities, and postoperative complications graded using the Clavien-Dindo classification. Statistical analysis uses linear mixed models to evaluate effects of group, time, and group-by-time interaction.
Because blinding of patients and surgeons was not feasible given the nature of the surgical intervention, outcome assessment relied on objective anthropometric and clinical measures. This record reflects a planned interim analysis conducted on the first 75 of a planned total of 100 enrolled patients, with 51 patients having completed 12-month follow-up at the time of this analysis.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Nurbol Orynbassar
- Telefonnummer: +77474528797
- E-Mail: nurbolorynbassar@gmail.com
Studienorte
-
-
-
Almaty, Kasachstan
- Rekrutierung
- JSC "National Scientific Center of Surgery named after A.N. Syzganov"
-
Kontakt:
- Nurbol Orynbassar
- Telefonnummer: +77474528797
- E-Mail: nurbolorynbassar@gmail.com
-
Hauptermittler:
- Adil Shokebaev
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age between 18 and 65 years
- BMI ≥35 kg/m² in non-Asian populations or ≥32.5 kg/m² in Asian populations
- Presence or absence of metabolic comorbidities (including type 2 diabetes, hypertension, and dyslipidaemia)
- Eligibility for primary one-anastomosis gastric bypass (OAGB)
- Provision of written informed consent
Exclusion Criteria:
- BMI below the defined thresholds
- Severe decompensated cardiac, pulmonary, hepatic, or renal disease
- Acute inflammatory conditions
- Active gastric or duodenal ulcer
- Psychiatric disorders or substance abuse
- Pregnancy or breastfeeding
- Active malignancy
- Severe intra-abdominal adhesions due to prior surgery
- Secondary obesity related to hypothalamic-pituitary-adrenal axis disorders
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: TSBL-Based Group
Biliopancreatic limb length (BPL) individualized based on intraoperatively measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL.
|
Biliopancreatic limb length individualized intraoperatively based on measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL, prior to laparoscopic one-anastomosis gastric bypass.
|
|
Aktiver Komparator: BMI-Based Group
Biliopancreatic limb length (BPL) determined using standard fixed lengths based on BMI category: 150 cm for BMI 35-39.9,
180 cm for BMI 40-49.9,
200 cm for BMI ≥50.
|
Biliopancreatic limb length determined using standard fixed lengths based on preoperative BMI category (150 cm, 180 cm, or 200 cm), prior to laparoscopic one-anastomosis gastric bypass.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Excess Weight Loss (%EWL)
Zeitfenster: Baseline, 3 months, 6 months, and 12 months post-surgery
|
EWL defined as the proportion of weight loss relative to excess baseline weight, with ideal body weight defined as BMI 25 kg/m².
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Total Weight Loss (%TWL)
Zeitfenster: Baseline, 3 months, 6 months, and 12 months post-surgery
|
TWL assessed as percentage of total body weight loss relative to baseline weight.
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Change
Zeitfenster: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Change in body mass index (BMI, kg/m²) from baseline over time.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Loss (BMIL)
Zeitfenster: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Reduction in BMI from baseline, expressed as BMI loss (BMIL).
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
Improvement in Obesity-Related Comorbidities
Zeitfenster: 12 months post-surgery
|
Change in obesity-related comorbidities, including hypertension and ischemic heart disease, compared between groups.
|
12 months post-surgery
|
|
Postoperative Complications
Zeitfenster: 12 months post-surgery
|
Postoperative complications documented and categorized according to the Clavien-Dindo classification system, including anaemia, hair loss, and bowel movement disorder.
|
12 months post-surgery
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TSBL-BMI-OAGB
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .